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alternative to surgery.700 mg/m2 intravenous on days 1 to 4 and CDDP at 70 mg/m2 intravenous on day 1,
repeated every 4 weeks for 2 cycles. Radiation therapy consisted of 60 Gy in 30 frac-
tions. After completion of CRT, 2 additional cycles of CTwith 5-FU (800 mg/m2, days
1-5) and CDDP (80 mg/m2, day 1) were repeated at a 4-week interval. The primary
endpoint was 3-year overall survival.
Results: Thirty patients were enrolled across 8 institutions in Japan, consisting of 26
men and 4 women with a median age of 64.5 years (range, 50-75 years). No grade 4
hematologic toxicity was seen in the CRT phase, and 1 grade 4 thrombocytopenia was
seen in the CT phase. Grade 3 nonhematologic acute toxicities in the CRT phase were
nausea (10%), mucositis (13.3%), and dysphagia (13.3%). No treatment-related death
in either phase occurred. Overall complete response rate was 73%, and 3-year overall
and laryngectomy-free survival were 66.5% and 52.5%, respectively. Regarding T4
disease, 3-year overall and laryngectomy-free survival were 58.3% and 38.5%, respec-
tively.
Conclusions: This study, the first prospective study for cervical esophageal cancer,
showed that CRT has sufficient efficacy and safety for use as an alternative to surgery
for these patients.  2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Cervical esophageal cancer is a rare disease that accounts
for only 2% to 10% of all cases of esophageal cancer (1, 2).
Previous prospective studies of esophageal cancer excluded
(3-6) or enrolled only a few patients with cervical esoph-
ageal cancer (7). For this reason, reliable information on the
clinical profile of chemoradiotherapy (CRT) for cervical
esophageal cancer is scarce. In general, although high-
quality evidence supports a recommended radiation ther-
apy dose for tumors of the thoracic esophagus of 50 to
50.4 Gy, higher doses (>60 Gy) for tumors of the cervical
esophagus may be acceptable (8), albeit evidence for this
was not prospective. Several reports have described CRT
for cervical esophageal cancer (9-12), but these were all
retrospective analyses, and treatment regimens or planned
radiation doses and methods have not been unified.
Moreover, hypopharyngeal cancer and cervical esopha-
geal cancer are often treated by the same surgical approach
(ie, total pharyngo-laryngo-esophagectomy) (2, 13-17), and
only a few studies have focused exclusively on cervical
esophageal cancer (18, 19). As a result, a standard,
evidence-based approach to squamous cell carcinoma of
the cervical esophagus has yet to be developed.
Here, we conducted a prospective study to clarify the
clinical profile of CRT for pure cervical esophageal cancer.
The regimens used in this study were carefully discussed
before the study was started.
With regard to radiation oncology, because the prophy-
lactic irradiation field for cervical esophageal cancer differs
from the thoracic esophagus, which includes the heart and
lung, we considered that irradiation of >60 Gy would be
safe. On the other hand, the risk of stenosis of the esophagus
as a late toxicity with 70-Gy irradiation, the standard dose inhead and neck cancer, seemed problematic. Accordingly, we
established 60 Gy as an optimal irradiation dose.
From a medical oncology standpoint, cisplatin (CDDP)
with concurrent radiation therapy is the gold standard in
head and neck cancer, and platinum-based regimens are
also accepted.
In contrast, 5-fluorouracil (5-FU)-based regimens seem
to be standard in esophageal cancer.
The larynx, which is included within the irradiation area,
is more susceptible to severe mucositis induced by 5-FU
and radiation therapy than the thoracic esophagus.
Accordingly, we determined that the amount of 5-FU
should be set lower than that in the Radiation Therapy
Oncology Group protocol 85-01.Patients and Methods
This study was conducted under a multicenter, single-arm,
phase 2 design. The study protocol was approved by the
institutional review boards of all participating institutions,
and written informed consent to treatment was obtained
from all patients before trial entry. This trial was registered
with the UMIN clinical trials registry.Patients
Patients with operable cervical esophageal cancer fulfilling
the following criteria were enrolled: histologically
confirmed squamous cell carcinoma of cervical esophagus;
age 20 to 75 years; Eastern Cooperative Oncology Group
performance status between 0 and 1; normal organ func-
tion; and N0-1 disease, including superior mediastinum
lymph nodes above the tracheal bifurcation.
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were excluded if the upper aspect of the tumor extended
cranially beyond the level of the hyoid or if the lower end
extended caudally beyond the aortic arch. Patients with T1
disease who were candidates for endoscopic resection or
who were not candidates for laryngectomy were also
excluded.
Pretreatment clinical evaluation included air contrast
barium esophagography; upper gastrointestinal endoscopy;
and cervical, chest, and abdominal computed tomography.
Radiologic evaluation for staging was jointly reviewed by
radiologists, surgeons, and oncologists. Tumor staging was
performed using the 6th edition of the International Union
Against Cancer TNM classification. Positron emission to-
mography (PET) was not used routinely because of do-
mestic reasons (routine use of PETecomputed tomography
for staging and response evaluation was not accepted by
government health insurance).
Treatment regimens
The treatment protocol consisted of concurrent CRT and
additional chemotherapy (CT) (Fig. 1).
First, patients received concurrent CRT with 5-FU plus
CDDP. Our protocol permitted the construction of a
percutaneous endoscopic gastrostomy before the start of
CRT. Chemotherapy consisted of 5-FU at a dose of 700 mg/
m2 intravenous on days 1 to 4 and CDDP at 70 mg/m2
intravenous on day 1, repeated every 4 weeks for 2 cycles.
Radiation therapy consisted of 60 Gy in 30 fractions over
6 weeks, delivered with megavoltage equipment (6 MV)CRT phase
(4 days)
(5 days)
1 2 3
1 2 3
CT phase
700mg/m2x4
800mg/m2x5
80mg/m2
70mg/m2
RT
(60 Gy/30fr)
CDDP
5-FU
5-FU
CDDP
Fig. 1. Protocol treatment schema. The treatment protocol co
tional chemotherapy (CT). Additional CT was limited to patien
ations: 5-FU Z 5-fluorouracil; CDDP Z cisplatin; RT Z radiausing the multiple-field technique. Computed tomogra-
phyebased 3-dimensional treatment planning was required
for all enrolled patients. The initial clinical target volume
(CTV1) included the primary tumor with a 2-cm margin for
subclinical craniocaudal extension, metastatic lymph
nodes, and regional lymph nodes. The initial planning
target volume (PTV1) was defined as the CTV1 plus 1 to
2 cm craniocaudally and 0.5 to 1 cm circumferentially, with
compensation for internal organ motion and daily setup
variation. The lower neck, supraclavicular, upper medias-
tinal, and subcarinal lymph nodes were included in the
prophylactic irradiation field. The boost CTV (CTV2)
included the primary tumor with a 1- to 2-cm margin for
subclinical craniocaudal extension and metastatic lymph
nodes. The boost PTV (PTV2) included CTV2 with
adequate margins. The PTV1 was irradiated with up to
40 Gy in 20 fractions, before a booster dose of 20 Gy in 10
fractions was delivered to PTV2. Irradiation using 4 or
more portals was strongly recommended to avoid excessive
dosing to the spinal cord near the primary site. Dose con-
straints for normal tissue were defined as follows: spinal
cord, <48 Gy; and lung, V10 <50%, V15 <40%, and V20
<25% (CRT phase).
For patients achieving an objective response after CRT, 2
additional cycles of CT with 5-FU (800 mg/m2, days 1-5)
and CDDP (80 mg/m2, day 1) were repeated at 4-week in-
tervals, starting 4 weeks after the completion of CRT (CT
phase). When a patient achieved complete response (CR)
after the completion of additional CT, additional treatment
was not permitted unless recurrence was observed. When a
patient had persistent disease or recurrence after completion4 5 6  (Week)
4 5 6  (Week)
nsisted of concurrent chemoradiotherapy (CRT) and addi-
ts who achieved an objective response after CRT. Abbrevi-
tion therapy.
Table 1 Patient characteristics (nZ30)
Characteristic Value
Age (y), median (range) 64.5 (50-75)
Sex (n), male/female 26/4
Performance status (n), 0-1/2 30/0
Stage
I (nZ3) T1N0M0, nZ3
IIA (nZ1) T2N0M0, nZ1
T3N0M0, nZ0
IIB (nZ8) T1N1M0, nZ5
T2N1M0, nZ3
III (nZ13) T3N1M0, nZ3
T4N0M0, nZ5
T4N1M0, nZ5
IV (nZ5) T2N1M1, nZ1*
T3N1M1, nZ1*
T4N1M1, nZ3*
* Upper mediastinal lymph node metastases.
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protocol treatment.
The CRT phase was defined from the initiation of radi-
ation therapy to 2 weeks after the end of radiation therapy.
The CT phase was defined from day 1 of additional 5-FU/
CDDP to 8 weeks after day 1 of additional 5-FU/CDDP.
Assessment of response evaluation
For lymph node metastases and new lesions, response was
evaluated according to Response Evaluation Criteria in
Solid Tumors version 1.0 with CT. Positron emission to-
mography was not used.
Response evaluation of the primary site was done using
endoscopic evaluation criteria (20) when observation of the
entire esophagus satisfied all of the following criteria: (1)
disappearance of the tumor lesion; (2) disappearance of
ulceration (slough); and (3) absence of cancer cells in bi-
opsy specimens. An evaluation of CR was not obviated by
the presence of erosion, a granular protruded lesion, ulcer
scar, or Lugol-voiding lesion.
The first evaluation was carried out 28 days after the
completion of CRT, and the second after the completion of
4 cycles of CT (21). Endoscopic assessments were repeated
every 4 weeks until primary CR or progressive disease was
confirmed.
Assessment of toxicities
Toxicities were graded using the Common Terminology
Criteria for Adverse Events version 3.0.
In the present study, toxicity profiles in the CRT and CT
phases were reported separately. Basically, late toxicity was
reported in periodic monitoring every 12 months using the
case report form.
Follow-up
After CR in the primary site and lymph nodes was
confirmed, radiologic and endoscopic evaluations were
performed in accordance with the follow-up program pre-
scribed in the protocol (File E01; available online at www
.redjournal.org).
Endpoints and statistical analyses
The primary endpoint of this study was 3-year overall
survival rate. Because prospective data were scarce, we
estimated 3-year overall survival rate from a retrospective
study (19) as 40%. When 3-year overall survival rate was
below 20%, the study treatment was to considered to pro-
vide insufficient organ preservation as an alternative to
surgery. Accordingly, the expected 3-year overall survival
rate and threshold were set at 40% and 20%. With 80%
power and a 1-sided type 1 error of 5%, the minimum
number of patients required to evaluate the primaryendpoint was 32. Allowing that 10% of patients might be
excluded by protocol violation or other reasons, we
calculated a total sample size of 35 patients.
Overall survival time was calculated from the start of
treatment to the date of death or the last confirmed date of
survival. Survival time was censored at the last confirmed
date of survival if the patient was alive. Progression-free
survival (PFS) time was defined from the day of initiation
of treatment to the first day of confirmation of progressive
disease at any site or any cause of death. Laryngectomy-
free survival (LFS) time was calculated from the start of
treatment to the first day of confirmation of laryngectomy
or any cause of death. Overall survival time, PFS time, and
LFS time were estimated by the Kaplan-Meier product-
limit method using commercially available statistical soft-
ware (StatView version 5.0, SAS Institute, Cary, NC).
The correlation of T stage with overall survival, PFS,
and LFS was investigated using the log-rank test.Results
Patients
Recruitment was discontinued early because of slow
accrual. From January 2009 through August 2012, 33 pa-
tients were enrolled across 8 sites in Japan. Three patients
were excluded from analysis because of patient discretion
(nZ1) and a change in strategy before the start of protocol
treatment (nZ2). The remaining 30 patients are charac-
terized in Table 1. Eighteen patients had stage III to IV
disease, and of those, 13 had T4 disease.
Safety profile
Twenty-nine of 30 patients (97%) completed radiation ther-
apy. Median duration of radiation therapy was 43.5 days
Table 2 Toxicity
Toxicity
Grade (CTCAE version 3.0)
1 2 3 4
% 3
and 4
CRT phase (nZ30)
Leucopenia 7 13 4 0 13.3
Neutropenia 6 11 2 0 6.7
Anemia 11 7 0 0 0
Thromobocytopenia 6 3 0 0 0
Nausea 3 3 3 0 10
Anorexia 4 0 0 0 0
Mucositis
CE 9 7 2 0 6.7
FS 6 8 4 0 13.3
Dysphagia 12 6 4 0 13.3
Dermatitis 14 8 0 0 0
Fistula 0 0 0 2* 6.7
Neuropathy (sensory) 1 1 0 0 0
Neuropathy (motor) 0 0 0 0 0
Weight loss 12 7 0 0 0
Renal function 8 1 0 0 0
Chemotherapy phase (nZ23)
Leucopenia 6 8 5 0 21.9
Neutropenia 7 3 7 0 30.4
Anemia 9 9 2 0 8.7
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dose of CT during radiation therapy. Relative dose intensity
in the CRT phase was 98.1% for CDDP and 99.4% for 5-FU.
One patient developed a grade 4 fistula of the esophagus
during radiation therapy and stopped protocol treatment.
The average pre- and post-CRT weight of all patients
was 58.6 kg (range, 37.4-81.4 kg) and 54.5 kg (range, 35.8-
77.2 kg), respectively.
Median percentage of weight loss during CRTwas 6.4%
(range, 0.2%-13.4%). Grade 2 weight loss (>10% weight
loss) occurred in 7 patients, whereas no grade 3 weight loss
(>20%) was seen.
Twenty-three patients received at least 1 course of addi-
tional CT. Drop-out was due to duodenal ulcer in 1, worsened
performance status in 1, progressive disease in 2, hearing loss
in 1, and patient refusal in 2. Nineteen patients received 2
courses of additional CT, and relative dose intensity in the CT
phasewas 56.0% for CDDP and 57.1% for 5-FU. Seven cases
(7 of 23, 30.4%) developed grade 3 neutropenia, whereas
there was no case of febrile neutropenia. One grade 4
thrombocytopenia was seen in the CT phase.
Toxicity profile in the CRT and CT phases is outlined in
Table 2. No treatment-related death was seen in either the
CRT or CT phase.Thromobocytopenia 7 3 0 1 4.3
Nausea 10 6 0 0 0
Anorexia 6 5 1 0 4.3
Mucositis
CE 4 0 1 0 4.3
FS 4 1 1 0 4.3
Dysphagia 5 5 0 0 0
Dermatitis 4 1 0 0 0
Neuropathy (sensory) 3 3 0 0 0
Neuropathy (motor) 0 1 0 0 0
Hand-foot syndrome 0 0 0 0 0
Renal function 8 1 0 0 0
Abbreviations:CEZ clinical examination;CRTZ chemoradiotherapy;
CTCAE Z Common Terminology Criteria for Adverse Events; FS ZEfficacy
The overall CR rate was 73.3% (22 of 30), and the CR rate at
the primary site was 76.7% (23 of 30). With a median follow-
up period of 40.8 months, 3-year overall survival was 66.5%
(95% confidence interval 40.6%-77.3%). Three-year PFS and
LFS rates were 36.6% and 52.5%, respectively (Fig. 2).
Three-year overall survival in patients with overall CRwas
74.6%, whereas that in patients with overall non-CR was
25.0%, with this difference being significant (PZ.002)
(Fig. 3).functional/symptomatic.
* Duodenal fistula induced by ulcer in 1, which might not be related
to radiation therapy.Failure pattern and second-line treatment
Eleven patients showed no recurrence on follow-up. In
those with recurrence, the initial failure pattern was local
recurrence only in 9, local recurrence with lymph node
metastases in 2, local recurrence with distant metastases in
2, lymph node metastases only in 4, and distant metastases
in 2. With regard to the 13 patients with local recurrence, 5
patients underwent salvage surgery, and 3 remained alive
for more than 3 years. One patient received photodynamic
therapy and was alive with an intact larynx. Three patients
received CT, and the remaining 3 received no further
anticancer treatment. Outcomes are listed in File E02
(available online at www.redjournal.org).
There were a total of 15 events of local failure in the
present study, and there were 7 events of distant failure and
7 patients who died without distant failure.The 3-year local failure-free survival rate estimated by
the Kaplan-Meier product-limit method was 43.3% (Fig. 3).Late toxicity and cause of death
With regard to late toxicity, 5 cases of grade 1 radiation
pneumonitis have been reported at this point, and no fatal
pneumonitis has been seen. Four patients without disease
have received endoscopic dilatation of the esophagus
because of esophageal stenosis after CRT.
Twelve patients died during study observation, 11 due to
progressive disease and 1 due to another cause (pancreatic
cancer).
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Fig. 2. Survival. Kaplan-Meier plots of overall, progression-free, and laryngectomy-free survival. Minimum follow-up
period in patients alive at data fixation was 759 days.
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Among the 13 patients with T4 disease, CR rate at the
primary site was 53.8% (7 of 13). Four of 6 patients with
residual disease at the primary site received salvage sur-
gery, of whom 2 survived.
Regarding laryngeal preservation, laryngectomy-free
survival tended to be worse with T4 disease, albeit without
statistical significance (PZ.10), whereas no significant dif-
ference was seen in 3-year overall survival (PZ.34).
Discussion
This is the first prospective study of CRT for cervical
esophageal cancer. With active median follow-up of
40.8 months, 3-year overall survival and LFS were 66.5%
and 52.5%, respectively. The overall CR rate was 73.3%(22 of 30), and 3-year overall survival in patients with
overall CR was 74.6%.
For T4 disease, the overall CR rate was 54% and 3-year
overall survival and LFS were 58.3% and 38.5%,
respectively.
Accordingly, CRT has sufficient efficacy and safety to
be considered an alternative treatment to surgery in patients
with cervical esophageal cancer.
Because the cervical esophagus is located closely ante-
rior to the spinal cord, providing sufficient radiation dosage
for the posterior wall of the esophagus while sparing the
spinal cord using the conventional technique is difficult. It
is therefore necessary to take advantage of qualified radi-
ation techniques, such as conformal radiation therapy.
Although we used a 3-dimensional multiple-field technique
in the present study, intensity modulated radiation therapy
may also solve the problem of proximity and be easier in
current clinical practice.
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Fig. 3. Survival and tumor response, survival and T stage. Three-year local failure-free survival rate was 46.6%, and 3-year
overall survival rate in patients with overall complete response (CR) (solid line) was significantly better than that in patients
with overall non-CR (broken line) (PZ.002). Three-year laryngectomy-free survival rate in patients with T4 disease (broken
line) was 38.5%, versus 62.6% in non-T4 disease patients (solid line). Three-year overall survival rate in patients with T4
disease (broken line) was 46.2%, versus 76.5% in those with non-T4 disease (solid line).
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CDDP and 99.4% for 5-FU, and was thus considered suf-
ficient. We initially considered that acute toxicities
(mucositis and dermatitis) might be more frequent with
cervical esophageal cancer and had set the CDDP and 5-FU
dosages slightly below the 75 to 100 mg/m2 for CDDP on
day 1 and 750 to 1000 mg/m2 for 5-FU on days 1 to 4
recommended for thoracic esophageal cancer. Further
improvement in the dose setting of these anticancer agents
seems possible.
Median percentage of body weight loss during CRT was
6.4% (range, 0.2%-13.4%), and >10% weight loss occurred
in 7 patients (23.3%). In our protocol, although construc-
tion of a percutaneous endoscopic gastrostomy before the
start of CRT was permitted, nutritional management wasnot described in detail. If nutritional management had been
considered in detail, the frequency of grade 2 weight loss
might have been reduced. The lack of nutritional infor-
mation in detail is one of the limitations in this study.
Although a phase 3 study would always be preferable,
the infrequency/rarity of cervical esophageal cancer may
render this all but impossible. At the planning stage, we
expected our study would be considered among the highest-
level evidence available for this condition, and even though
it was a phase 2 study, we selected overall survival as an
optimal index for primary endpoint.
Among the few articles on surgical approaches involving
more than 50 patients reported to date, Triboulet et al (14)
reported a 3-year overall survival rate in 78 cases of cer-
vical esophageal cancer of 22%, whereas a recent study
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cases of 42%. Several groups reported a significantly worse
prognosis for cervical esophageal cancer than hypophar-
yngeal cancer using a surgical approach (13, 14, 17). Our
present results are substantially better than these historical
controls, even allowing for differences in background
factors.
Laryngeal preservation is an important aim for patients
with carcinoma of the hypopharynx, larynx, and cervical
esophagus. In the present study the 3-year LFS rate was
52.5% for all T stages, and 38.5% for T4 disease. Our
protocol treatment can play an important role in laryngeal
preservation in patients at any T stage.
In contrast, 9 patients underwent salvage surgery after
CRT.
No severe complication occurred in salvage surgery, and
6 patients (66%) remain alive at writing without disease
after salvage surgery. Our results showed that even if the
laryngeal preservation strategy fails, some patients can
achieve a disease-free status by salvage surgery. Chemo-
radiotherapy as an initial treatment can achieve a sufficiently
good outcome only after appropriate salvage treatment
support.
Two recent large-scale retrospective studies of nonsur-
gical approaches for cervical esophageal cancer (11, 12)
provide substantial information to guide clinical practice,
but differed with regard to failure sites. Cao et al (12) re-
ported that the main site of failure was the primary site in
115 cervical esophageal cancer patients treated with
(chemo)radiotherapy. In contrast, Zhang et al (11) reported
that the main site was not the primary site but a distant
organ in 102 cervical esophageal cancer patients treated
with platinum-based CRT. We speculate that one cause of
these contradictory results may be that these retrospective
studies inadvertently included patients with hypophar-
yngeal cancer, in whom the field setting for prophylactic
lymph node irradiation might have been insufficient. In any
case, the main initial site of failure in our study was the
primary site, and distant metastasis as a first failure site was
seen in only 4 patients (4 of 30, 13.3%).
Three major limitations of our study warrant mention.
First is the proportion of cases of different tumor stages.Table 3 Published previous reports about outcomes of cervical eso
First author Year Study design N Stage I/II/III/IV Tr
Burmeister 2000 Retrospective 34 4/20/7/3 5-FU
Cao 2014 Retrospective 161 1/46/114/0 RT or
Zhang 2015 Retrospective 102 0/32/70/0 Platin
CR
Triboulet 2001 Retrospective 78 - Surge
Daiko 2007 Retrospective 74 6/30/38/0 Surge
Present study 2016 Phase 2 30 2/9/13/15 5-FU
Abbreviations: 3YOS Z 3-year overall survival; 5-FU Z 5-fluor
CRT Z chemoradiotherapy; DM Z distant metastases; RT Z radiation therapBecause this is a rare disease, we could not expect to enroll
an optimum range of patients before the start of the study.
To minimize the biases arising from this limitation, our
protocol required that patients with T1 disease who were
candidates for endoscopic resection or who were not can-
didates for laryngectomy should also be excluded. In our
study, 11 early-stage (I/II) patients were included, but all
were candidates for total laryngectomy who requested
laryngeal preservation. Previous retrospective studies have
also included early-stage patients in their reported clinical
outcomes. A historical comparison of patient characteris-
tics and outcomes from previous reports is shown in
Table 3.
Second, recruitment had to be discontinued early owing
to slow accrual. The main reason is the very low occurrence
of cervical esophageal cancer. Similarly, Triboulet et al’s
study (14) required 17 years to recruit 78 patients (4.6 cases
per year). Complete accumulation would likely have taken
an additional year; and given the good results obtained, this
lower number did not impact the statistical analysis. We
therefore decided to close the study early and publish the
data available at that time.
Third was the difference of tumor staging and response
evaluations. Tumor staging was performed using the 6th
edition of International Union Against Cancer TNM clas-
sification because this study was conducted from 2007.
Additionally, PETecomputed tomography for staging or
response evaluation was not used routinely, because in
Japan, not all institutions provided this examination
routinely in 2007, and routine use of PETecomputed to-
mography for staging and response evaluation was not
accepted by government health insurance.
These may be slightly different from current clinical
practice in United States and other countries.
In conclusion, our study, the first prospective trial of
CRT for cervical esophageal cancer, showed that CRT has
sufficient efficacy and safety to be considered an alternative
to surgery in these patients. Development of CT regimens
or radiation techniques may improve clinical outcomes in
the near future. Given this condition’s status as an orphan
disease, further multicenter and multination prospective
investigations are mandatory.phageal cancer
eatment Outcomes Comments
/CDDP/RT 5YOS 55% 3 different CRT regimens
CRT 2YOS 47.6% Median follow-up period: 17.1 mo
Main failure site: primary site
um-based
T
3YOS 39.3% Hypopharyngeal extention: 22.5%
Main failure site: DM
ryþ (RT) 3YOS 22% 20 patients had T1 disease
ry 3YOS 42% Cervical esophagectomy or TE
with or without TP
/CDDP/RT 3YOS 66.5%
ouracil; 5YOS Z 5-year overall survival; CDDP Z cisplatin;
y; TE Z total esophagectomy; TP Z total pharyngectomy.
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